{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:54:07Z","timestamp":1765234447555,"version":"3.44.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"am","delay-in-days":414,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.therap.2020.05.009","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T11:24:13Z","timestamp":1589973853000},"page":"319-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Drugs acting on renin angiotensin system and use in ill patients with COVID-19"],"prefix":"10.1016","volume":"75","author":[{"given":"Joachim","family":"Alexandre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Cracowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Bouhanick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10229","key":"10.1016\/j.therap.2020.05.009_bib0330","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.therap.2020.05.009_bib0335","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.therap.2020.05.009_bib0340","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res"},{"issue":"43","key":"10.1016\/j.therap.2020.05.009_bib0345","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J Biol Chem"},{"issue":"17","key":"10.1016\/j.therap.2020.05.009_bib0350","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.therap.2020.05.009_bib0355","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1038\/s41598-020-61250-5","article-title":"Angiotensin-[1\u20137] attenuates kidney injury in experimental Alport syndrome","volume":"10","author":"Choi","year":"2020","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.therap.2020.05.009_bib0360","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1124\/pr.114.010454","article-title":"Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli [corrected]","volume":"67","author":"Karnik","year":"2015","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.therap.2020.05.009_bib0365","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/angiotensin-(1-7)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7)","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol Rev"},{"issue":"6","key":"10.1016\/j.therap.2020.05.009_bib0370","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/HYPERTENSIONAHA.114.03743","article-title":"Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism","volume":"64","author":"Deshotels","year":"2014","journal-title":"Hypertension"},{"issue":"14","key":"10.1016\/j.therap.2020.05.009_bib0375","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1161\/01.CIR.0000160867.23556.7D","article-title":"G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor","volume":"111","author":"Kostenis","year":"2005","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.therap.2020.05.009_bib0380","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med"},{"issue":"6891","key":"10.1016\/j.therap.2020.05.009_bib0385","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.therap.2020.05.009_bib0390","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"issue":"7047","key":"10.1016\/j.therap.2020.05.009_bib0395","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.therap.2020.05.009_bib0400","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41368-020-0074-x","article-title":"High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa","volume":"12","author":"Xu","year":"2020","journal-title":"Int J Oral Sci"},{"issue":"21","key":"10.1016\/j.therap.2020.05.009_bib0405","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1007\/s00018-004-4242-5","article-title":"Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus","volume":"61","author":"Kuhn","year":"2004","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"10.1016\/j.therap.2020.05.009_bib0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"7807","key":"10.1016\/j.therap.2020.05.009_bib0415","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.therap.2020.05.009_bib0420","article-title":"Structure analysis of the receptor binding of 2019-nCoV","author":"Chen","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"issue":"7807","key":"10.1016\/j.therap.2020.05.009_bib0425","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.therap.2020.05.009_bib0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.therap.2020.05.009_bib0435","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.bbrc.2004.05.114","article-title":"Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor","volume":"319","author":"Hofmann","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.therap.2020.05.009_bib0440","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.coph.2006.03.001","article-title":"Angiotensin-converting enzyme 2 in lung diseases","volume":"6","author":"Kuba","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.therap.2020.05.009_bib0445","article-title":"Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19)","author":"Chen","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.therap.2020.05.009_bib0450","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.21656","article-title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics","author":"Gurwitz","year":"2020","journal-title":"Drug Dev Res"},{"issue":"3","key":"10.1016\/j.therap.2020.05.009_bib0455","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci China Life Sci"},{"issue":"4","key":"10.1016\/j.therap.2020.05.009_bib0460","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.therap.2020.05.009_bib0465","article-title":"ACE2 Activators for the treatment of Covid 19 patients","author":"Puertas","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.therap.2020.05.009_bib0470","doi-asserted-by":"crossref","first-page":"104833","DOI":"10.1016\/j.phrs.2020.104833","article-title":"Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor","volume":"157","author":"Li","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.therap.2020.05.009_bib0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","author":"Monteil","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.therap.2020.05.009_bib0480","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit Care Lond Engl"},{"issue":"21","key":"10.1016\/j.therap.2020.05.009_bib0485","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1007\/s00018-004-4240-7","article-title":"Angiotensin-converting enzyme-2: a molecular and cellular perspective","volume":"61","author":"Warner","year":"2004","journal-title":"Cell Mol Life Sci"},{"issue":"Pt\u00a01","key":"10.1016\/j.therap.2020.05.009_bib0490","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism","volume":"383","author":"Rice","year":"2004","journal-title":"Biochem J"},{"issue":"5","key":"10.1016\/j.therap.2020.05.009_bib0495","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","article-title":"Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors","volume":"43","author":"Ishiyama","year":"2004","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.therap.2020.05.009_bib0500","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1161\/01.HYP.0000237862.94083.45","article-title":"Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat","volume":"48","author":"Ocaranza","year":"2006","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.therap.2020.05.009_bib0505","doi-asserted-by":"crossref","first-page":"e0198144","DOI":"10.1371\/journal.pone.0198144","article-title":"Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease","volume":"13","author":"Ramchand","year":"2018","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.therap.2020.05.009_bib0510","first-page":"1280","article-title":"Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling","volume":"19","author":"Walters","year":"2017","journal-title":"Europace"},{"issue":"10","key":"10.1016\/j.therap.2020.05.009_bib0515","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1097\/00004872-200410000-00020","article-title":"Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation","volume":"22","author":"Campbell","year":"2004","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.therap.2020.05.009_bib0520","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/00004872-199606000-00017","article-title":"Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension","volume":"14","author":"Luque","year":"1996","journal-title":"J Hypertens"},{"key":"10.1016\/j.therap.2020.05.009_bib0525","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/HYPERTENSIONAHA.120.15082","article-title":"Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers","volume":"75","author":"Danser","year":"2020","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.therap.2020.05.009_bib0530","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41569-020-0368-x","article-title":"Interaction between RAAS inhibitors and ACE2 in the context of COVID-19","volume":"17","author":"Mourad","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"10.1016\/j.therap.2020.05.009_bib0535","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.RES.0000187500.24964.7A","article-title":"Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients","volume":"97","author":"Keidar","year":"2005","journal-title":"Circ Res"},{"issue":"1\u20133","key":"10.1016\/j.therap.2020.05.009_bib0540","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.regpep.2010.09.005","article-title":"Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression","volume":"166","author":"Zhong","year":"2011","journal-title":"Regul Pept"},{"key":"10.1016\/j.therap.2020.05.009_bib0545","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvaa097","article-title":"Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19","author":"Kreutz","year":"2020","journal-title":"Cardiovasc Res"},{"issue":"19","key":"10.1016\/j.therap.2020.05.009_bib0550","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/eurheartj\/ehaa311","article-title":"Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts","volume":"41","author":"Nicin","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.therap.2020.05.009_bib0555","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1863","article-title":"Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence","author":"Sriram","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2020.05.009_bib0560","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1741-7015-2-19","article-title":"ACE2 gene expression is up-regulated in the human failing heart","volume":"2","author":"Goulter","year":"2004","journal-title":"BMC Med"},{"issue":"30","key":"10.1016\/j.therap.2020.05.009_bib0565","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.2174\/0929867324666170414162841","article-title":"Circulating ACE2 in cardiovascular and kidney diseases","volume":"24","author":"Anguiano","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.therap.2020.05.009_bib0570","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2004500","article-title":"Covid-19 in critically ill patients in the Seattle region\u00a0\u2014\u00a0Case series","author":"Bhatraju","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2020.05.009_bib0575","doi-asserted-by":"crossref","first-page":"m1313","DOI":"10.1136\/bmj.m1313","article-title":"Drugs and the renin-angiotensin system in covid-19","volume":"369","author":"Aronson","year":"2020","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.therap.2020.05.009_bib0580","doi-asserted-by":"crossref","first-page":"e016509","DOI":"10.1161\/JAHA.120.016509","article-title":"Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers have a biphasic effect?","volume":"9","author":"Sommerstein","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.therap.2020.05.009_bib0585","doi-asserted-by":"crossref","first-page":"e016219","DOI":"10.1161\/JAHA.120.016219","volume":"9","author":"Guo","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.therap.2020.05.009_bib0590","article-title":"Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","author":"Zhang","year":"2020","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.therap.2020.05.009_bib0595","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect"},{"year":"2020","series-title":"D\u00e9claration de la Soci\u00e9t\u00e9 europ\u00e9enne d\u2019hypertension (ESH) sur l\u2019hypertension, concernant les bloqueurs du syst\u00e8me R\u00e9nine Angiotensine et la maladie COVID-19 caus\u00e9e par le coronavirus SARS-CoV-2","author":"Soci\u00e9t\u00e9 fran\u00e7aise d\u2019hypertension art\u00e9rielle","key":"10.1016\/j.therap.2020.05.009_bib0600"},{"year":"2020","series-title":"HFSA\/ACC\/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. American College of Cardiology","key":"10.1016\/j.therap.2020.05.009_bib0605"},{"issue":"19","key":"10.1016\/j.therap.2020.05.009_bib0610","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/eurheartj\/ehaa235","article-title":"SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?","volume":"41","author":"Kuster","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.therap.2020.05.009_bib0615","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.regpep.2013.03.005","article-title":"Effects of felodipine combined with puerarin on ACE2-Ang (1-7)-Mas axis in renovascular hypertensive rat","volume":"184","author":"Bai","year":"2013","journal-title":"Regul Pept"},{"issue":"4","key":"10.1016\/j.therap.2020.05.009_bib0620","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/1470320309343710","article-title":"Angiotensin II reduces membranous angiotensin-converting enzyme 2 in pressurized human aortic endothelial cells","volume":"10","author":"Iizuka","year":"2009","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"4","key":"10.1016\/j.therap.2020.05.009_bib0625","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/hr.2012.187","article-title":"Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats","volume":"36","author":"Takai","year":"2013","journal-title":"Hypertens Res"},{"issue":"5","key":"10.1016\/j.therap.2020.05.009_bib0630","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/1074248419838503","article-title":"AHU377+valsartan (LCZ696) modulates renin-angiotensin system (RAS) in the cardiac of female spontaneously hypertensive rats compared with valsartan","volume":"24","author":"Zhao","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.therap.2020.05.009_bib0635","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jash.2007.10.005","article-title":"Differential effect of low dose thiazides on the Renin Angiotensin system in genetically hypertensive and normotensive rats","volume":"2","author":"Jessup","year":"2008","journal-title":"J Am Soc Hypertens"},{"issue":"4","key":"10.1016\/j.therap.2020.05.009_bib0640","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s11255-019-02074-9","article-title":"Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes","volume":"51","author":"Dong","year":"2019","journal-title":"Int Urol Nephrol"},{"issue":"8","key":"10.1016\/j.therap.2020.05.009_bib0645","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1253\/circj.72.1346","article-title":"Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes","volume":"72","author":"Yamamuro","year":"2008","journal-title":"Circ J"},{"issue":"3","key":"10.1016\/j.therap.2020.05.009_bib0650","doi-asserted-by":"crossref","first-page":"H1013","DOI":"10.1152\/ajpheart.00068.2005","article-title":"Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats","volume":"289","author":"Igase","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720300998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720300998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:25Z","timestamp":1758567205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720300998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0040595720300998"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.05.009","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs acting on renin angiotensin system and use in ill patients with COVID-19","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}